Trial Profile

An international Overall Survival clinical study with the combination of Ceplene and low dose Proleukin.

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 21 Feb 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Feb 2017 According to an Immune Pharmaceuticals media release, company will announce the launch of this trial at the Acute Leukemia XVI symposium 2017. Patient recruitment is expected to start in later 2017.
22 Nov 2016 According to an Immune Pharmaceuticals media release, following the guidance from the Food and Drug Administration, the Ceplene Scientific Advisory Board (SAB) will review the proposed clinical protocol of this study.
27 Oct 2016 According to an Immune Pharmaceuticals media release, company has received guidance from the United States Food and Drug Administration (FDA) on this study. FDA reviewed the study design and provided feedback relating to specific design elements. Company plans to submit the final protocol for the phase III study in early 2017.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com